Form 4: Gilead Sciences SVP, Controllership, Sandra Patterson, Reports Stock Transactions

Sandra Patterson, SVP, Controllership at Gilead Sciences, reported the acquisition and disposal of company stock and restricted stock units on December 13, 2023 and December 13, 2024.

Summary

• Sandra Patterson, a Senior Vice President at Gilead Sciences, reported multiple transactions involving the company's common stock and restricted stock units.
• On December 13, 2023, she acquired 181, 117 and 157 shares of common stock through the vesting of restricted stock units.
• Also on December 13, 2023, 298 shares were disposed of for tax withholding purposes at a price of $83.09 per share.
• On December 13, 2024, 157 shares were disposed of for tax withholding purposes at a price of $91.855 per share.
• Following these transactions, Ms. Patterson beneficially owns 37,078 shares of Gilead Sciences common stock.
• She also holds 11,827 restricted stock units that will vest over time.

Sentiment

Score: 7

Explanation: The document is a routine SEC filing detailing stock transactions by an executive. It is neutral in nature and expected as part of standard compensation practices.

Industry Context

This is a routine SEC Form 4 filing, which is common for corporate officers who receive stock-based compensation. It provides transparency into insider transactions.

Comparison to Industry Standards

• The vesting schedules of three and four years for restricted stock units are typical for executive compensation packages in the pharmaceutical industry.
• The tax withholding process is a standard practice when restricted stock units vest.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect standard executive compensation practices.

Key Dates

Keywords

Gilead Sciences, stock transactions, restricted stock units, insider trading, SEC Form 4, vesting, tax withholding, Sandra Patterson